
The acquisition is conditional on approved Due Diligence. The fixed purchase sum is financed by a corporate acquisition loan of EUR 3 million and by payment of EUR 2 million in newly issued shares or cash. If payment is in shares, this is planned to be carried out after distribution of the subsidiary Xvivo Perfusion AB. Vitrolife anticipates that the acquisition will have a marginally negative effect on earnings per share for 2012 due to increased marketing activities and transaction expenses but that the business will make a positive contribution as from 2013.
Cryo Management Ltd and its subsidiary Cryo Innovation Ltd are located in Budapest, Hungary. The company was formed in 2005, and has 20 employees and budgeted sales of approximately EUR 2 million for 2012. The company has successfully developed, produced and marketed time-lapse products, primarily for the IVF market.
New implant replaces damaged middle ear
2012-12-21
Hearing damage is the most common physical handicap in the industrialised world. People who are functionally deaf can now achieve normal hearing thanks to a new implant that...
Professor Jens Nielsen awarded by Nature
Medfield Diagnostics: New MD takes office in January
Region Västra Götaland Delegation Visit to India
Vacant positions within the biotech and life science area in the Göteborg region.
Here you find a list of current calls for proposals and applications for Life Science!